Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Ovarian Cancer Treatment Market: By Cancer Type, BY Treatment Type, By Route of Administration By Distribution Channel By End User and Region Forecast 2020-2031
Ovarian Cancer Treatment Market size was valued at US$ 2,146.8 million in 2024 and is expected to reach US$ 3,751.4 million by 2031, growing at a significant CAGR of 8.3% from 2025-2031. Moreover, the U.S. Ovarian Cancer Treatment Market is projected to grow significantly, reaching an estimated value of US$ 1,170.4 Million by 2031. Ovarian cancer is a type of cancer in which abnormal growth of cells originates from the tissues of the epithelial or outer lining of the ovaries and fallopian tubes. The various factors, such as a mutation in the genes and a family history of ovarian cancer, are significant causes of ovarian cancer in women. The Global Ovarian Cancer Therapeutics Market is primarily driven by the rising incidence of ovarian cancer and its late-stage diagnosis, which necessitate immediate and aggressive treatment strategies. The increasing awareness, aging population, and genetic predispositions like BRCA mutations further escalate demand for advanced therapeutics.
A key trend reshaping the market is the rapid adoption of precision medicine, particularly targeted therapies such as PARP inhibitors and antibody–drug conjugates, which have improved patient outcomes and are becoming first-line options. Additionally, the integration of AI and genomic profiling is revolutionizing early detection and treatment personalization. Opportunities abound in developing novel biomarkers and companion diagnostics that can enable early diagnosis and real-time monitoring, along with expanding immunotherapies and CAR-T cell research. Growth in emerging markets driven by rising healthcare investment and infrastructure also presents significant potential.
However, the market faces restraints in the form of high treatment costs, limited reimbursement frameworks, and access disparities in low-resource settings. Regulatory delays and therapy-related side effects further compound adoption challenges. Despite these barriers, the overall outlook remains optimistic, backed by technological advances and a robust innovation pipeline targeting unmet clinical needs.
Based on the cancer type:
Epithelial ovarian cancer holds the highest market share among the three cancer types in the global ovarian cancer therapeutics market. This dominance is due to its high prevalence, accounting for approximately 85–90% of all ovarian cancer cases. Epithelial tumors often originate from the outer lining of the ovaries and are typically diagnosed at an advanced stage due to vague early symptoms, leading to increased demand for aggressive treatments such as chemotherapy, targeted therapies, and combination regimens. Its significant incidence drives most clinical trials, drug development efforts, and awareness campaigns. In contrast, stromal tumors and germ cell tumors represent a much smaller portion of the market, with germ cell tumors being the rarest. These occur mostly in younger women and often have better prognoses and simpler treatment protocols.
Based on the treatment type:
Targeted therapy drugs hold the highest market share in the global ovarian cancer therapeutics market, driven by their high efficacy, personalized approach, and growing adoption in advanced and recurrent cases. Among these, PARP inhibitors have gained widespread use, especially for patients with BRCA mutations or homologous recombination deficiencies, offering significant survival benefits with fewer side effects. Angiogenesis inhibitors also play a key role in controlling tumour growth by cutting off the blood supply. The preference for targeted therapies is increasing due to their ability to improve outcomes and reduce toxicity compared to traditional treatments. In contrast, radiation therapy holds the smallest market share, as it is rarely used in ovarian cancer management due to the cancer’s diffuse spread and better efficacy of systemic therapies, making it a limited option in current clinical practice.
Based on the route of administration:
Among the routes of administration, intravenous (IV) therapy holds the largest market share in the global ovarian cancer therapeutics market. This dominance is due to the widespread use of IV administration for delivering chemotherapy, targeted therapy, and immunotherapy drugs directly into the bloodstream, ensuring faster and more effective drug action. IV delivery allows for precise dosing, better control over drug infusion rates, and immediate patient monitoring, which is crucial in managing advanced-stage ovarian cancer. While oral therapies like PARP inhibitors are gaining traction due to convenience and patient compliance, they are often used in maintenance settings. Intraperitoneal therapy holds the smallest share due to complexity, higher complication rates, and limited adoption outside specialized centers.
Based on the distribution channel:
Hospital pharmacies hold the highest market share in the global ovarian cancer therapeutics market due to their central role in dispensing high-cost and complex oncology medications, especially during inpatient treatment and chemotherapy sessions. They are equipped to manage advanced cancer therapies, including targeted drugs and combination regimens, under close medical supervision. Hospital settings also facilitate multidisciplinary care, ensuring the timely administration of treatments and immediate management of adverse effects, which enhances their importance. Additionally, oncology drugs often require refrigeration and controlled environments, which hospital pharmacies are better equipped to provide. In contrast, online pharmacies hold the smallest market share due to regulatory limitations, challenges in delivering specialized medications, and the preference for in-person clinical oversight when handling potent cancer drugs.
Based on the end user:
Among end users, hospitals hold the largest market share in the Global ovarian cancer therapeutics market. This is primarily because hospitals serve as comprehensive care centers offering diagnosis, surgery, chemotherapy, and advanced treatments under one roof. They are typically equipped with specialized oncology departments, multidisciplinary care teams, and advanced infrastructure, which makes them the primary point of care for most ovarian cancer patients, especially during initial diagnosis and intensive treatment phases. Oncology centers are also gaining momentum due to their focused expertise and personalized care models. Specialty clinics, though important for follow-ups and outpatient therapies, serve a smaller portion of the market. Meanwhile, research institutions, while crucial for clinical trials and drug development, represent the smallest market share due to their limited direct patient care role.
Study Period
2025-2031Base Year
2024CAGR
8.3%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
One major driver of the global ovarian cancer market is the increasing incidence and late-stage diagnosis of ovarian cancer, which necessitates aggressive and advanced treatment options. Due to the disease’s vague early symptoms, over 70% of cases are detected at advanced stages, where therapeutic intervention becomes critical. This rising burden is pushing demand for improved diagnostic tools, targeted therapies, and combination treatments.
Moreover, heightened awareness campaigns and screening initiatives in high-risk populations are leading to more frequent diagnoses. The rising elderly female population and genetic risk factors, such as BRCA mutations, also contribute significantly to market growth. In addition to these, advancements in immunotherapy, companion diagnostics, and government funding for oncology research are other crucial drivers fueling the expansion of the market.
One major restraint of the market is the high cost associated with advanced treatment options, particularly next-generation hormone therapies, immunotherapies, and precision medicines. These treatments often require long-term administration, sophisticated diagnostics, and follow-up, making them unaffordable for many patients, especially in low- and middle-income countries. Limited reimbursement coverage in certain regions further exacerbates access issues, resulting in treatment delays or suboptimal care. In resource-constrained settings, this financial barrier severely restricts the use of innovative therapies, despite clinical efficacy.
Moreover, healthcare systems face challenges in integrating expensive therapies into standard protocols without burdening payers. Alongside cost, other significant restraints include the side effects of therapies such as fatigue, bone loss, and cardiovascular risks, which can impact patient compliance and quality of life. In addition, late-stage diagnosis in many patients reduces the therapeutic window for effective treatment, and regulatory hurdles can delay the approval and availability of newer drugs.
One of the most promising opportunities in the global ovarian cancer therapeutics market lies in the development of novel biomarkers and companion diagnostics that enable early detection and tailored treatments. Since most ovarian cancer cases are diagnosed at an advanced stage, improving early-stage diagnosis through liquid biopsies, ctDNA, or miRNA-based markers can dramatically increase survival rates. These innovations offer the chance to monitor disease progression in real-time, improving treatment responsiveness. Another major opportunity is the expansion of immunotherapies, including cancer vaccines and checkpoint inhibitors, especially when combined with targeted therapies like PARP inhibitors or ADCs. Clinical trials exploring CAR-T cell therapy for ovarian tumors also signal future breakthroughs.
Additionally, growth in emerging markets due to rising awareness, better healthcare access, and increasing government investments further supports global expansion. As regulatory pathways for accelerated drug approvals become more streamlined, biotech firms and pharma companies are aggressively pursuing pipeline diversification, unlocking significant commercial and clinical potential.
A major trend in the global ovarian cancer market is the shift toward precision-guided targeted therapies, especially the growing use of PARP inhibitors and antibody–drug conjugates (ADCs). PARP inhibitors, which exploit genetic vulnerabilities in BRCA-mutated and homologous recombination-deficient tumors, held the largest market share in 2024. ADCs like mirvetuximab soravtansine (Elahere) are offering targeted delivery of chemotherapy with fewer side effects and have demonstrated a 35% reduction in progression risk compared to traditional chemotherapy. these approaches enhance treatment precision, reduce toxicity, and improve survival, ushering in a new era of personalized care.
Other notable trends include the rise of liquid biopsies and cell-free DNA assays for early detection, AI-driven diagnostics to support genomic profiling, and the implementation of umbrella/basket trial designs that fast-track therapy development
Report Benchmarks |
Details |
Report Study Period |
2025-2031 |
Market Size in 2024 |
US$ 2,146.8 million |
Market Size in 2031 |
US$ 3,751.4 million |
Market CAGR |
8.3% |
By Cancer Type |
|
By Treatment Type |
|
By Route of Administration |
|
By Distribution Channel |
|
By End User |
|
By Region |
|
According to a PBI analyst, the global ovarian cancer therapeutics market is undergoing a transformative shift driven by late-stage diagnoses, rising prevalence, and increasing demand for personalized treatment approaches. The growing adoption of targeted therapies like PARP inhibitors and antibody–drug conjugates, supported by advancements in genomic profiling and liquid biopsy technologies, is significantly improving patient outcomes and quality of care.
Additionally, innovations in early detection and immunotherapy are expanding the treatment landscape. While high treatment costs and access limitations in low- and middle-income countries pose challenges, the market is expected to grow steadily due to increased awareness, supportive government initiatives, and investment in oncology research. Overall, the market holds strong long-term potential, especially with emerging opportunities in diagnostics and AI-assisted care strategies.
Download Free Sample Report
The ovarian cancer treatment market size was valued at US$ 2,146.8 million in 2024 and is projected to grow at a significant CAGR of 8.3% from 2025-2031.
The increasing incidence of ovarian cancer, rising awareness, better screening, genetic risk factor identification, innovations like PARP inhibitors, and immunotherapies are accelerating the market.
Targeted therapy drugs, particularly PARP inhibitors, hold the highest market share due to superior survival benefits and FDA approvals. They are widely adopted in BRCA-mutated cases and platinum-sensitizing relapses. Other segments like immunotherapy and hormone therapy are gaining traction but remain smaller.
Market research is segmented based on cancer type, treatment type, route of administration, distribution channel, end user, and region.
Asia-Pacific is the fastest-growing region due to the rising prevalence of an aged population, rising healthcare expenditures, increased government support, and an expanding target patient pool
1.Executive Summary |
2.Global Ovarian Cancer Treatment Market Introduction |
2.1.Global Ovarian Cancer Treatment Market - Taxonomy |
2.2.Global Ovarian Cancer Treatment Market - Definitions |
2.2.1.Cancer Type |
2.2.2.Treatment Type |
2.2.3.Route of Administration |
2.2.4.Distribution Channel |
2.2.5.Region |
3.Global Ovarian Cancer Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Ovarian Cancer Treatment Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Ovarian Cancer Treatment Market By Cancer Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
5.1. Epithelial ovarian cancer |
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Stromal tumors |
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Germ cell tumors |
5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6.Global Ovarian Cancer Treatment Market By Treatment Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
6.1. Targeted therapy drugs |
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Immunotherapy drugs |
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Chemotherapy drugs |
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Hormone therapy drugs |
6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Radiation therapy |
6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
7.Global Ovarian Cancer Treatment Market By Route of Administration, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
7.1. Oral |
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Intravenous |
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Intraperitoneal |
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Ovarian Cancer Treatment Market By Distribution Channel, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
8.1. Hospital Pharmacies |
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Retail Pharmacies |
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Online Pharmacies |
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Specialty Distribution Centers. |
8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
9.Global Ovarian Cancer Treatment Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10.North America Ovarian Cancer Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
10.1. Cancer Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Epithelial ovarian cancer |
10.1.2.Stromal tumors |
10.1.3.Germ cell tumors |
10.2. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Targeted therapy drugs |
10.2.2.Immunotherapy drugs |
10.2.3.Chemotherapy drugs |
10.2.4.Hormone therapy drugs |
10.2.5.Radiation therapy |
10.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Oral |
10.3.2.Intravenous |
10.3.3.Intraperitoneal |
10.4. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Hospital Pharmacies |
10.4.2.Retail Pharmacies |
10.4.3.Online Pharmacies |
10.4.4.Specialty Distribution Centers. |
10.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11.Europe Ovarian Cancer Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
11.1. Cancer Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Epithelial ovarian cancer |
11.1.2.Stromal tumors |
11.1.3.Germ cell tumors |
11.2. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Targeted therapy drugs |
11.2.2.Immunotherapy drugs |
11.2.3.Chemotherapy drugs |
11.2.4.Hormone therapy drugs |
11.2.5.Radiation therapy |
11.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Oral |
11.3.2.Intravenous |
11.3.3.Intraperitoneal |
11.4. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.Hospital Pharmacies |
11.4.2.Retail Pharmacies |
11.4.3.Online Pharmacies |
11.4.4.Specialty Distribution Centers. |
11.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
12.Asia Pacific (APAC) Ovarian Cancer Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
12.1. Cancer Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Epithelial ovarian cancer |
12.1.2.Stromal tumors |
12.1.3.Germ cell tumors |
12.2. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Targeted therapy drugs |
12.2.2.Immunotherapy drugs |
12.2.3.Chemotherapy drugs |
12.2.4.Hormone therapy drugs |
12.2.5.Radiation therapy |
12.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Oral |
12.3.2.Intravenous |
12.3.3.Intraperitoneal |
12.4. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.Hospital Pharmacies |
12.4.2.Retail Pharmacies |
12.4.3.Online Pharmacies |
12.4.4.Specialty Distribution Centers. |
12.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13.Middle East and Africa (MEA) Ovarian Cancer Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
13.1. Cancer Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Epithelial ovarian cancer |
13.1.2.Stromal tumors |
13.1.3.Germ cell tumors |
13.2. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Targeted therapy drugs |
13.2.2.Immunotherapy drugs |
13.2.3.Chemotherapy drugs |
13.2.4.Hormone therapy drugs |
13.2.5.Radiation therapy |
13.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Oral |
13.3.2.Intravenous |
13.3.3.Intraperitoneal |
13.4. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Hospital Pharmacies |
13.4.2.Retail Pharmacies |
13.4.3.Online Pharmacies |
13.4.4.Specialty Distribution Centers. |
13.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14.Latin America Ovarian Cancer Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
14.1. Cancer Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Epithelial ovarian cancer |
14.1.2.Stromal tumors |
14.1.3.Germ cell tumors |
14.2. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Targeted therapy drugs |
14.2.2.Immunotherapy drugs |
14.2.3.Chemotherapy drugs |
14.2.4.Hormone therapy drugs |
14.2.5.Radiation therapy |
14.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Oral |
14.3.2.Intravenous |
14.3.3.Intraperitoneal |
14.4. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.Hospital Pharmacies |
14.4.2.Retail Pharmacies |
14.4.3.Online Pharmacies |
14.4.4.Specialty Distribution Centers. |
14.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.Mylan N.V. (U.S.) |
15.2.2.Teva Pharmaceutical Industries Ltd. (Ireland) |
15.2.3.Sanofi (France) |
15.2.4.Pfizer Inc. (U.S.) |
15.2.5.GlaxoSmithKline plc (U.K.) |
15.2.6.Novartis AG (Switzerland) |
15.2.7.Bayer AG (Germany) |
15.2.8.Eli Lilly and Company (U.S.) |
15.2.9.Merck & Co., Inc. (U.S.) |
15.2.10.Allergan (Ireland) |
15.2.11.AstraZeneca (U.K.) |
15.2.12.Johnson & Johnson Private Limited (U.S.) |
15.2.13.Cipla Inc. (U.S.) |
15.2.14.Abbott (U.S.) |
15.2.15.AbbVie Inc. (U.S.) |
15.2.16.Merck KGaA (Germany) |
15.2.17.LEO Pharma A/S (Denmark) |
15.2.18.Bausch Health Companies Inc. (Canada) |
15.2.19.Sun Pharmaceutical Industries Ltd. (India) |
15.2.20.Aurobindo Pharma (India) |
15.2.21.Lupin (India) |
15.2.22.Hikma Pharmaceuticals PLC (U.K.) |
15.2.23.Amneal Pharmaceuticals LLC. (U.S.) |
16. Research Methodology |
17. Appendix and Abbreviations |
Key Market Players